Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | RBP1 | P09455 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 8/20 | 0.55 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819129 | 1.00 | DAGLA (0.67) | DAGLANAAARBP1CNR1CNR2 | |
| SCHEMBL18179105 | 0.88 | DAGLA (0.63) | DAGLANAAARBP1CNR1CNR2 | |
| SCHEMBL22046217 | 0.88 | DAGLA (0.63) | DAGLANAAARBP1CNR1CNR2 | |
| SCHEMBL16769853 | 0.82 | DAGLA (0.64) | DAGLANAAARBP1CNR1CNR2 | |
| SCHEMBL23776171 | 0.82 | DAGLA (0.64) | DAGLANAAARBP1CNR1CNR2 | |
| SCHEMBL26052569 | 0.81 | DAGLA (0.71) | DAGLANAAARBP1CNR1CNR2 | |
| Cannabidiolic Acid SCHEMBL23029816 | 0.80 | DAGLA (1.00) | DAGLANAAACNR1CNR2TRPV1 | |
| Cannabidiolic Acid SCHEMBL15159497 | 0.80 | DAGLA (1.00) | DAGLANAAACNR1CNR2TRPV1 | |
| Cannabidiolic Acid SCHEMBL141666 | 0.80 | DAGLA (1.00) | DAGLANAAACNR1CNR2TRPV1 | |
| Cannabidiolic Acid SCHEMBL16224866 | 0.80 | DAGLA (1.00) | DAGLANAAACNR1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212100-A1 | SYSTEMS AND METHODS FOR REFINING CANNABIDIOL | Mile High Labs, Inc. (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212100-A1 | SYSTEMS AND METHODS FOR REFINING CANNABIDIOL | BROX, CNR2, DDOST | DAGLA 5/4885NAAA 899/4885RBP1 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.